1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and...
-
Upload
benjamin-terry -
Category
Documents
-
view
223 -
download
0
Transcript of 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and...
![Page 1: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/1.jpg)
1
Raloxifene for the Reduction in the Risk of Invasive Breast Cancer
July 24, 2007
Eli Lilly and Company
Oncologic Drugs Advisory CommitteePresentation
![Page 2: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/2.jpg)
2
Lilly’s Presentation
• Introduction Gwen Krivi, PhDEli Lilly and Company
• Benefits and Risks of Evista
– MORE/CORE/RUTH Steven R. Cummings, MDDirector, San Francisco Coordinating CenterProfessor of Medicine and Epidemiology
(emeritus) CPMC Research Institute and UC San Francisco
– STAR Larry Wickerham, MDNSABP STAR Project OfficerNational Surgical Adjuvant Breast and Bowel
Project (NSABP)
– Conclusions George Sledge, MDBallve Lantero Professor of OncologyIndiana University School of Medicine
![Page 3: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/3.jpg)
3
Expert Participants
Eli Lilly and Company
Bruce Mitlak, MD (moderator)
John Mershon, MD
Dan Masica, MD
Michelle McNabb, MS
Jingli Song, PhD
Matt Rotelli, PhD
Dan Brady, PhD
Additional External Consultants
Joseph Costantino, DrPHDirector, NSABP Biostatistical CenterNational Surgical Adjuvant Breast and Bowel Project (NSABP)
Norman Wolmark, MDChairman, NSABPNational Surgical Adjuvant Breast and Bowel Project (NSABP)
![Page 4: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/4.jpg)
4
Why Is Breast Cancer Risk Reduction Important?
• 2nd most common cause of cancer death in women • 178,000 cases diagnosed annually
• 40,000 deaths annually
• Disease prevention remains an unmet need in breast cancer
• Identification of women at risk continues to improve
• Postmenopausal women need additional options to reduce risk of breast cancer
![Page 5: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/5.jpg)
5
Raloxifene is aSelective Estrogen Receptor Modulator
• Non-steroidal ligand of the estrogen receptor
• Has estrogen-like effects in some tissues
• Blocks estrogen effects in other tissues
Evista® (raloxifene HCl 60 mg/day) is approved for the prevention and treatment of osteoporosis
![Page 6: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/6.jpg)
6
Raloxifene Development HistoryBreast Cancer (1982-1998)
1982-1990 IND for treatment of Breast Cancer opened with the Oncology Division
1992 IND for osteoporosis opened with Endocrine Division
1994 MORE study initiated (breast cancer – secondary endpoint)
1998 IND for invasive breast cancer risk reduction opened
IND for STAR opened by NSABP
RUTH study initiated (CV risk reduction)
![Page 7: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/7.jpg)
7
Raloxifene Development HistoryBreast Cancer (1999 – present)
1999 CORE study initiated (follow-up to MORE; invasive breast cancer – primary endpoint)
2000 RUTH protocol amended to add invasive breast cancer as a second primary endpoint
2005 Pre-NDA meetings with the Oncology Division
2006 Invasive breast cancer risk reductionNDA submitted
![Page 8: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/8.jpg)
8
Evista®: Current Indication
Proposed Additional Indication
The prevention and treatment of osteoporosis.
The reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.
![Page 9: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/9.jpg)
9
Evista®: Current Indication
Proposed Additional Indication
The prevention and treatment of osteoporosis.
The reduction in risk of invasive breast cancer in postmenopausal women at high risk for breast cancer.
![Page 10: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/10.jpg)
10
Studied in More Than 37,000 PostmenopausalWomen Across a Spectrum of Breast Cancer Risk
Randomized active comparator trial
Study of Tamoxifen and Raloxifene (STAR)
Randomized placebo-controlled trials
Raloxifene Use for The Heart Trial (RUTH)
Multiple Outcomes of Raloxifene Evaluation (MORE)
Placebo-controlled follow-up study of MORE participants
Continuing Outcomes Relevant to Evista (CORE)
76,000 patient years of exposure to raloxifene
![Page 11: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/11.jpg)
11
Multiple Outcomes of Raloxifene EvaluationMORE
Continuing Outcomes Relevant to EvistaCORE
Raloxifene Use for The Heart Trial RUTH
Steven R. Cummings, MDDirector, San Francisco Coordinating Center
Professor of Medicine and Epidemiology (emeritus)CPMC Research Institute and UC San Francisco
![Page 12: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/12.jpg)
12
Study DesignMORE
• International multicenter, double-blind, placebo-controlled
• 7705 postmenopausal women with osteoporosis; excluded women with a history of breast cancer
• Raloxifene 60 mg, 120 mg, or placebo daily
• 3 years with 1 year extension
• Primary objectives: radiographic vertebral fracture, bone mineral density
![Page 13: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/13.jpg)
13
Secondary ObjectivesMORE
• All fractures
• Cardiovascular health
• Breast cancer
• Endometrial cancer
• Cognitive function and dementia
• Health outcomes
![Page 14: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/14.jpg)
14
Ascertainment and Validation of Invasive Breast Cancer
• Mammograms or ultrasound required at baseline
• Mammograms were performed at years 2, 3, & 4
• All investigator-reported breast cancers were reviewed and adjudicated by a board of breast cancer specialists
– blinded to treatment assignment
– not employed by Lilly
![Page 15: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/15.jpg)
15
Baseline CharacteristicsMORE
N=5133*
Mean age 66.9 years
Caucasian 95.9%
Family history of breast cancer 12.5%
Hysterectomy 23.1%
Previous hormone therapy 29.3%
* Placebo and raloxifene 60 mg/day only
![Page 16: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/16.jpg)
16
Raloxifene Is Approved for the Preventionand Treatment of Osteoporosis
MOREC
linic
al v
erte
bral
frac
ture
spe
r 10
00 w
oman
-yrs
5.2 fewer fractures per 1000/yr
HR = 0.57 (95% CI, 0.42-0.78)
43% decreased risk
![Page 17: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/17.jpg)
17Year
0 1 2 3 4
Cum
ulat
ive
inci
denc
e pe
r 10
00 w
omen
0
5
10
15
20
25
30Placebo (n=38)Raloxifene 60 mg (n=11)
RR = 0.29 (95% CI = 0.15-0.56)p-value <0.0001
Invasive Breast CancerMORE
3.1 fewer cases per 1000/yr
![Page 18: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/18.jpg)
18Year
0 1 2 3 4
Cum
ulat
ive
inci
denc
e pe
r 10
00 w
omen
0
5
10
15
20
25
30Placebo (n=38)Raloxifene 60 mg (n=11)Raloxifene 120 mg (n=9)
Invasive Breast CancerMORE
![Page 19: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/19.jpg)
19
Invasive and Non-Invasive Breast CancersMORE
Invasive Non-Invasive Invasiveness
Inci
denc
e pe
r 10
00 w
oman
-yrs
0
1
2
3
4
5
PlaceboRaloxifene 60 mg
38
11
13
HR 0.29(95% CI=0.15-0.56)
53
HR 0.59(95% CI=0.14-2.47)
unknown
![Page 20: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/20.jpg)
20
Invasive Breast Cancer by ER StatusMORE
ER+ ER- ER unknown
Inci
denc
e pe
r 10
00 w
oman
-yrs
0
1
2
3
4
5
Placebo Raloxifene 60 mg
29
65
0
HR 0.20(95% CI=0.08-0.49)
4 5
HR 1.23(95% CI=0.33-4.60)
![Page 21: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/21.jpg)
21
Study DesignCORE
• Double-blind, placebo-controlled continuation of MORE
• Does raloxifene continue to reduce the risk of breast cancer after 4 years?
• 1° endpoint: invasive breast cancer
• 4011 women from MORE continued in CORE
![Page 22: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/22.jpg)
22
0 1 2 3 4Year
Placebo
Raloxifene 60 mg/day
Raloxifene 120 mg/day
Study Design MORE Followed by CORE: 8 Years
MORE(N=7705)
CORE(N=4011)
![Page 23: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/23.jpg)
23
0 1 2 3 4Year
Placebo
Raloxifene 60 mg/day
Raloxifene 120 mg/day
Placebo
Raloxifene 60 mg/day
Study Design MORE Followed by CORE
(N = 1286)
MORE(N=7705)
CORE(N=4011)
GapCORE
Screening
5 6 7 8
![Page 24: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/24.jpg)
24
0 1 2 3 4Year
Placebo
Raloxifene 60 mg/day
Raloxifene 120 mg/day
Placebo
Raloxifene 60 mg/day
Study Design MORE Followed by CORE
(N = 1286)
(N = 2725)
MORE(N=7705)
CORE(N=4011)
GapCORE
Screening
5 6 7 8
![Page 25: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/25.jpg)
25
0 1 2 3 4Year
Placebo
Raloxifene 60 mg/day
Raloxifene 120 mg/day
Placebo
Raloxifene 60 mg/day
Study Design MORE Followed by CORE: 8 Years
(N = 1286)
(N = 2725)
MORE(N=7705)
CORE(N=4011)
GapCORE
Screening
5 6 7 8
4 more years
![Page 26: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/26.jpg)
26
Breast Cancer AssessmentsCORE
• Baseline: 5-year risk of breast cancer by Gail Model
• Annual clinical breast exams
• Mammograms required at baseline and years 2 and 4
• Reports of breast cancer adjudicated by 3 breast cancer specialists
– who were blinded to patient treatment assignment
– who were not employed by Lilly
![Page 27: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/27.jpg)
27
5-Year Predicted Risk of Breast Cancer by Gail Model
CORE
PlaceboN=1286
RaloxifeneN=2725
Average 5-year predicted risk 1.94% 1.94%
Percent with 5-year predicted risk ≥1.66%
53% 54%
![Page 28: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/28.jpg)
28
0
1
2
3
4
5
6
7
Inci
den
ce p
er 1
000
wo
man
-yrs
Invasive Breast Cancer Risk ReductionCORE
HR, 0.44(95% CI 0.24-0.83)
p = 0.009
20
19
Placebo
N=1274
Raloxifene
N=2716
3.0 fewer cases per 1000/yr
![Page 29: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/29.jpg)
29
Raloxifene Reduced the Incidence of InvasiveBreast Cancer in Women with High or Low Risk
CORE
0
1
2
3
4
5
6
7
8
Inci
den
ce p
er 1
000
wom
an-
yrs
Placebo
Raloxifene
N=674 N=1475 N=604 N=1243
6
8
14
11
HR 0.35(95% CI, 0.16-0.78)
HR 0.65(95% CI, 0.23-1.87)
<1.66% ≥1.66%
5-year Predicted Invasive Breast Cancer Risk by Gail Score
1.2 fewer cases per
1000/yr
4.6 fewer cases per
1000/yr
![Page 30: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/30.jpg)
30
Raloxifene Reduced the Incidence of InvasiveBreast Cancer in Women with High or Low Risk
CORE
0
1
2
3
4
5
6
7
8
Inci
den
ce p
er 1
000
wom
an-
yrs
Placebo
Raloxifene
N=674 N=1475 N=604 N=1243
6
8
14
11
HR 0.35(95% CI, 0.16-0.78)
HR 0.65(95% CI, 0.23-1.87)
<1.66% ≥1.66%
5-year Predicted Invasive Breast Cancer Risk by Gail Score
1.2 fewer cases per
1000/yr
4.6 fewer cases per
1000/yr
Interactionp = 0.37
![Page 31: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/31.jpg)
31
Invasive Breast CancerRaloxifene 60 mg vs. Placebo
In women assigned to raloxifene 60 mg or placebo in both MORE and CORE over 8 years:
• 60% decrease: HR 0.40 (95% CI = 0.21-0.77)
![Page 32: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/32.jpg)
32
Raloxifene Use for The Heart Trial RUTH
![Page 33: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/33.jpg)
33
Background RUTH
• RUTH began enrollment in June, 1998
– It was believed that estrogen may reduce risk of CHD by improving lipoproteins and vascular function
– Raloxifene improved lipoproteins and fibrinogen
• Hypothesis: Treatment with raloxifene would reduce the risk of CHD events.
![Page 34: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/34.jpg)
34
Study DesignRUTH
• Randomized, double-blind, placebo-controlled
• Raloxifene 60 mg or placebo daily
• 10,101 postmenopausal women at high risk for coronary heart disease
• Primary Outcome
– Coronary heart disease events (CHD death, nonfatal MI, hospitalized acute coronary syndrome besides MI)
![Page 35: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/35.jpg)
35
• Randomized, double-blind, placebo-controlled
• Raloxifene 60 mg or placebo daily
• 10,101 postmenopausal women at high risk for coronary heart disease
• Primary Outcome
– Coronary heart disease events (CHD death, nonfatal MI, hospitalized acute coronary syndrome besides MI)
– Invasive breast cancer
Study DesignRUTH
![Page 36: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/36.jpg)
36
Characteristic
Age 67.5 years
Caucasian 84.0%
BMI 28.8 kg/m2
Current smoker 12.4%
Previous estrogen use 14.0%
Previous estrogen/progestin 6.1%
Baseline CharacteristicsRUTH
![Page 37: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/37.jpg)
37
CharacteristicTotal
(N=10,101)
Mean 5-yr estimated breast cancer risk 1.73%
Percent with 5-yr risk ≥1.66% 41.4%
Family history of breast cancer 9.8%
Prior breast biopsy 8.8%
Diagnosis of atypical hyperplasia 1.7%
Baseline Breast Cancer RiskRUTH
![Page 38: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/38.jpg)
38
No Effect on Coronary Events*RUTH
*First occurrence of non-fatal MI, hospitalized ACS or coronary death
![Page 39: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/39.jpg)
39
Significant Reduction inInvasive Breast Cancer Incidence
RUTH
1.2 fewer cases per 1000/yr
![Page 40: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/40.jpg)
40
Raloxifene Reduces the Incidence of Invasive Breast Cancer in Women with High or Low Gail Risk
RUTH
34
17
35
23
HR 0.65(95% CI, 0.38-1.09)
HR 0.49(95% CI, 0.28-0.88)
<1.66% ≥1.66%
5-year Predicted Invasive Breast Cancer Risk
1.1 fewer cases per
1000/yr
1.2 fewer cases per
1000/yr
![Page 41: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/41.jpg)
41
Raloxifene Reduces the Incidence of Invasive Breast Cancer in Women with High or Low Gail Risk
RUTH
34
17
35
23
HR 0.65(95% CI, 0.38-1.09)
HR 0.49(95% CI, 0.28-0.88)
<1.66% ≥1.66%
5-year Predicted Invasive Breast Cancer Risk
1.1 fewer cases per
1000/yr
1.2 fewer cases per
1000/yr
Interactionp-value = 0.50
![Page 42: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/42.jpg)
42
RUTH MORE CORE
Inci
denc
e pe
r 10
00 w
oman
-yrs
0
1
2
3
4
5
6PlaceboRaloxifene
71%
56%
44%
SummaryReductions in Invasive Breast Cancer
![Page 43: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/43.jpg)
43
Raloxifene Safety
![Page 44: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/44.jpg)
44
Adverse EventsMORE – 4 Years
Percent (%)
Placebo(n=2576)
Raloxifene(n=5129)
p-value
Thromboembolic disease 17 (0.7) 64 (1.3) 0.017
- deep vein thrombosis 8 (0.3) 44 (0.9) 0.005
- pulmonary embolism 4 (0.2) 22 (0.4) 0.060
Death 36 (1.4) 64 (1.2) 0.584
![Page 45: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/45.jpg)
45
Adverse EventsMORE – 4 Years
Percent (%)
Placebo(n=2576)
Raloxifene(n=5129)
p-value
Vaginal bleeding* 74 (3.7) 220 (3.7) 0.977
Endometrial hyperplasia* 5 (0.3) 11 (0.3) 0.846
Endometrial cancer* 5 (0.3) 8 (0.2) 0.707
Cataracts 141 (5.5) 257 (5.0) 0.386
Hot Flushes 151 (5.9) 512 (10.0) <.001
Leg Cramps 150 (5.8) 443 (8.6) <.001
Peripheral edema 134 (5.2) 340 (6.6) 0.014
*In participants with a uterus
![Page 46: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/46.jpg)
46
Balance of Efficacy and Safety OutcomesMORE
Difference in No. of Events per 1000/yr
-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3
Ovarian ca
Endo ca
VTE
Stroke
Death due to stroke
Death
Vert fx
NIBC
IBC
FAVORS RALOXIFENE FAVORS PLACEBO
![Page 47: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/47.jpg)
47
Balance of Efficacy and Safety OutcomesMORE
Difference in No. of Events per 1000/yr
-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3
Ovarian ca
Endo ca
VTE
Stroke
Death due to stroke
Death
Vert fx
NIBC
IBC
FAVORS RALOXIFENE FAVORS PLACEBO
![Page 48: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/48.jpg)
48
Endometrial and Uterine CancerRUTH, MORE, CORE
0
0.25
0.5
0.75
1
1.25
1.5
RUTH MORE CORE
Inci
de
nce
pe
r 1
00
0 w
om
an
-yrs
Placebo
Raloxifene
5
8
17
21 3
4
(N=5959) (N=3146)(N=7782)
Including only women with a uterus
![Page 49: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/49.jpg)
49
Safety SummaryRUTH
Compared to placebo, raloxifene was associated with:
• Increased risk of VTEs
• No effect on all-cause mortality
• No effect on all strokes
• Increased risk of death due to stroke
• Reduced risk of clinical vertebral fractures
![Page 50: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/50.jpg)
50
Safety Information in Evista Label
• Based on the osteoporosis prevention and treatment trials, MORE and CORE, the safety profile in the label includes:
– VTEs
– Hot flushes, leg cramps, peripheral edema
• Based on the RUTH trial, the label also states:
– Evista should not be used for the primary or secondary prevention of cardiovascular disease.
– Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. No increased risk of stroke was seen. Consider risk-benefit balance in women at risk for stroke.
![Page 51: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/51.jpg)
51
RUTH
Overall benefit risk profile is neutral in womenat high risk of cardiovascular disease
![Page 52: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/52.jpg)
52
An Additional Benefit for Women with Osteoporosis
• Raloxifene is indicated for osteoporosis
• Postmenopausal women considering Evista for osteoporosis should be informed about its effect on risk of breast cancer
![Page 53: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/53.jpg)
53
Study of Tamoxifen and RaloxifeneSTAR
Larry Wickerham, MD
NSABP STAR Project Officer
![Page 54: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/54.jpg)
54
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
# EventsPlacebo 93Tamoxifen 60
50
40
30
20
10
0
# EventsPlacebo 250Tamoxifen 145
50
40
30
20
10
0
Cu
mu
lati
ve R
ate/
1000
Invasive Breast Cancer
NoninvasiveBreast Cancer
Time to Breast Cancer (Years)
P < 0.0001
P= 0.008
NSABP P1 Study
![Page 55: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/55.jpg)
55
STRATIFICATION• Age• Gail Model Risk• Race• History of LCIS• Hysterectomy
Tamoxifen20 mg/dayx 5 years
Study DesignSTAR
Raloxifene60 mg/dayx 5 years
Risk-Eligible Postmenopausal Women
![Page 56: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/56.jpg)
56
Inclusion and Exclusion CriteriaSTAR
Inclusion
– At least 35 years of age
– Postmenopausal
– Risk eligible
Lobular carcinoma in situ or
5-year Gail risk of breast cancer >1.66%
Exclusion
History of:
– Invasive breast cancer
– Ductal carcinoma in situ
– DVT, PE
– CVA, TIA
– Uncontrolled diabetes, hypertension or atrial fibrillation
![Page 57: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/57.jpg)
57
Primary AimsSTAR
• The primary aim of the study was to determine which of the following three statements is true:
– Compared to tamoxifen, raloxifene significantly reduces the incidence rate of IBC
– Compared to raloxifene, tamoxifen significantly reduces the incidence rate of IBC
– The statistical superiority of one of the treatments cannot be demonstrated and the choice of therapy should be based on benefit/risk considerations
![Page 58: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/58.jpg)
58
Primary ObjectiveSTAR
Evaluate the effect of raloxifene versus tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk.
![Page 59: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/59.jpg)
59
Secondary Objectives STAR
•Non-invasive breast cancer
•Endometrial cancer
•Ischemic heart disease
•Fractures of the hip, spine or wrist
•Toxicity and side effects
![Page 60: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/60.jpg)
60
Screening, Accrual and Follow-upSTAR
Screened 184,460
Eligible 96,368
Randomized 19,747
Woman-years of follow-up 79,173
Average follow-up (years) 4.06
![Page 61: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/61.jpg)
61
Baseline CharacteristicsSTAR
Age (mean) 58.5
Caucasian 93%
Hysterectomy 51%
First degree relative(s)with breast cancer 71%
History of
Lobular carcinoma in situ 9%
Atypical hyperplasia 23%
5-year predicted Gail risk ofinvasive breast cancer (mean) 4.03%
![Page 62: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/62.jpg)
62
Effects on Invasive Breast Cancer STAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve in
cid
ence
per
100
0 w
om
en
0
5
10
15
20
25
30Tamoxifen (n=168)Raloxifene (n=173)
RR (95% CI) = 1.02 (0.82, 1.27)
![Page 63: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/63.jpg)
63
Invasive Breast Cancer STAR
0
2
4
6
8
10
12
Gail Model Expectedif Untreated
Tamoxifen Raloxifene
Inci
denc
e pe
r 10
00 w
oman
-yrs
168 173
325
![Page 64: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/64.jpg)
64
Invasive Breast Cancer by 5-year Predicted RiskSTAR
0
2
4
6
8
10
12
≤3% 3.01 - 5% ≥5.01%
Predicted 5-year Risk
Inci
denc
e pe
r 10
00 w
oman
-yrs
Tamoxifen
Raloxifene
33
63
72
4449
80
![Page 65: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/65.jpg)
65
Invasive Breast Cancer Tumor CharacteristicsSTAR
Tamoxifenn=168
Raloxifenen=173
Estrogen Receptor Status
+ 72% 69%
- 28% 31%
Tumor Size
<1 29% 39%
1.1-3 61% 54%
>3.1 10% 8%
Nodal Status
- 74% 80%
+ 26% 20%
![Page 66: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/66.jpg)
66
0
3
6
9
12
Inci
den
ce p
er 1
000
wo
man
-yrs Tamoxifen
Raloxifene
LCISN=1783
Atypical Hyperplasia N=4429
34 35
4741
Invasive Breast Cancer in Women with aHistory of LCIS or Atypical Hyperplasia
STAR
![Page 67: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/67.jpg)
67
Non-Invasive Breast Cancer STAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve
in
cid
en
ce
pe
r 1
00
0 w
om
en
0
5
10
15
20
25
30
Tamoxifen (n=60)Raloxifene (n=83)
RR (95% CI) = 1.38 (0.98-1.95)
![Page 68: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/68.jpg)
68
Non-Invasive Breast CancerSTAR
Tamoxifen(n)
Raloxifene(n)
RR (95%CI)
DCIS 32 47 1.46 (0.91-2.37)
LCIS 23 29 1.26 (0.70-2.27)
Mixed 5 7 1.39 (0.38-5.57)
![Page 69: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/69.jpg)
69
Uterine Cancer STAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve in
cid
ence
per
100
0 w
om
en
0
5
10
15
20
25
30Tamoxifen (n=37)Raloxifene (n=23)
RR (95% CI) = 0.61 (0.34, 1.05)
![Page 70: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/70.jpg)
70
Tamoxifen(n)
Raloxifene(n)
RR (95% CI)
Hysterectomyduring study
246 92 0.37 (0.28, 0.47)
Hyperplasia 100 17 0.17 (0.09, 0.28)
with atypia 15 2 0.13 (0.01, 0.56)
w/o atypia 85 15 0.17 (0.09, 0.30)
Uterine Hyperplasia and HysterectomySTAR
![Page 71: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/71.jpg)
71
Ischemic Heart Disease STAR
Tamoxifen(n)
Raloxifene(n)
RR (95% CI)
Myocardial infarction
53 39 0.73 (0.47-1.13)
Severe angina 55 71 1.28 (0.89-1.86)
Acute ischemic syndrome
17 28 1.64 (0.87-3.19)
Total 125 138 1.10 (0.86-1.41)
![Page 72: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/72.jpg)
72
Osteoporotic Fractures STAR
Tamoxifen(n)
Raloxifene(n)
RR (95% CI)
Hip 28 26 0.92 (0.52-1.63)
Spine 58 58 0.99 (0.68-1.46)
Wrist 27 27 0.99 (0.56-1.76)
Total* 111 108 0.97 (0.73-1.27)
*Columns not additive because one patient may have had fractures at multiple sites.
![Page 73: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/73.jpg)
73
MortalitySTAR
Tamoxifen(n)
Raloxifene(n)
Cancer 52 52
Breast cancer 5 2
Circulatory/vascular 25 21
Other 32 31
Any cause 109 104RR (95% CI)
0.95 (0.72-1.25)
![Page 74: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/74.jpg)
74
Venous Thromboembolic EventsSTAR
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve
in
cid
en
ce
pe
r 1
00
0 w
om
en
0
5
10
15
20
25
30Tamoxifen (n=150)Raloxifene (n=105)
RR (95% CI) = 0.69 (0.53, 0.90)
![Page 75: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/75.jpg)
75
Cataracts and Cataract Surgery During Follow-upSTAR
0
2
4
6
8
10
12
14
Cataracts Cataract Surgery
Incid
en
ce p
er
1000 w
om
an
-yrs Tamoxifen
Raloxifene435
295
343
240
RR = 0.78(95% CI = 0.68–0.91)
RR = 0.81(95% CI = 0.68–0.96)
![Page 76: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/76.jpg)
76
Summary STAR
Compared with tamoxifen, raloxifene was:
• similar in decreasing the risk of invasive breast cancer
• not as effective at decreasing the risk of non-invasive breast cancer
• associated with fewer:
– adverse events related to uterus
– VTEs
– cataracts and cataract surgery
![Page 77: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/77.jpg)
77
Risk Benefit and Conclusions
George Sledge, MDIndiana University School of Medicine
![Page 78: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/78.jpg)
78
Do We Need a New Chemoprevention Agent?
• Breast cancer continues to represent a major cause of morbidity and mortality
• Few women actually receive tamoxifen as chemoprevention for breast cancer
– Real toxicities (VTE, uterine cancer) limit its use
– Perception that it is a “cancer drug” with poor risk/benefit ratio
![Page 79: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/79.jpg)
79
Raloxifene Demonstrates Efficacyin Postmenopausal Women
Across a Spectrum of Breast Cancer Risk
RUTH MORE CORE STAR
Inci
den
ce p
er 1
000
wom
an-y
rs
0
1
2
3
4
5
6PlaceboTamoxifenRaloxifene
71%
56%
44%
RR 1.02
![Page 80: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/80.jpg)
80
Confirmation of Raloxifene’s Effectiveness Relative to Tamoxifen in STAR
STAR Non-inferiority Analysis Proportion retention of tamoxifen’s effect*
(95% CI) = 97% (65%, 128%)
Time Since Randomization (months)
0 6 12 18 24 30 36 42 48 54 60 66 72Cu
mu
lati
ve i
nci
den
ce p
er 1
000
wo
men
0
5
10
15
20
25
30Tamoxifen (n=168)Raloxifene (n=173)
STAR Primary AnalysisRR (95% CI) = 1.02 (0.82, 1.27)
* Tamoxifen’s effect based on women 50 years or older in P-1
![Page 81: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/81.jpg)
81
Raloxifene as an Alternative to Tamoxifen: Benefit
• Similar efficacy with regard to prevention of invasive breast cancer
– Less effect on noninvasive cancers
![Page 82: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/82.jpg)
82
Non-Invasive Breast Cancerin Placebo-Controlled Studies
MORE, CORE, RUTH
0
0.25
0.5
0.75
1
1.25
1.5
MORE CORE RUTH
Inc
ide
nc
e r
ate
pe
r 1
00
0 w
om
an
-yrs
PlaceboRaloxifene
11/50445/50572/1274 5/2716
(N=5133) (N=3990) (N=10,101)
5/2576 3/2557
SEER
SEER annual US incidence rate per 1,000 in white women ≥50 (2000 data)
![Page 83: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/83.jpg)
83
Efficacy and Important Safety Outcomes STAR
FAVORS RALOXIFENE FAVORS TAMOXIFEN
Difference in Number of Events (95% CI) per 1000 Women/Yr
P=0.055
P=0.057
*
*
*
**P < 0.05 vs. tamoxifen
![Page 84: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/84.jpg)
84
Difference in # of events per 1000treated per 5 years
(RALOXIFENE VS. TAMOXIFEN)
Non-invasive breast cancer 3 moreDCIS only 2 more
Hysterectomy 40 fewer†
Hyperplasia 20 fewer†
Uterine cancer 4 fewer
Venous thromboembolism 6 fewer†
Deep vein thrombosis 3 fewer Pulmonary embolism 3 fewer
Cataracts 10 fewer†
Cataract surgery 9 fewer†
Outcome
†P < 0.05
Differences in Outcomes forRaloxifene versus Tamoxifen
STAR
![Page 85: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/85.jpg)
85
1Sever PS et al., Lancet. 2003 Apr 5;361(9364):1149-582MRC Working Party Br Med J 1992;304:405-4123Berger JS et al. JAMA 2006;295:306-3134Fisher B et al., J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88.
Invasive Breast Cancer Risk Reduction Compares Favorably
with Other Prevention Therapies
Therapy Event NNT*
Atorvastatin1 MI/CHD death 294
Antihypertensives2 Strokes 370
Coronary event 417
Aspirin3 MI 753
Tamoxifen4 Invasive BrCa 303
Raloxifene (MORE) Invasive BrCa 323
Raloxifene (CORE) Invasive BrCa 335
Raloxifene (RUTH) Invasive BrCa 862
*NNT = number of patients needed to treat for 1 year to prevent 1 outcome
![Page 86: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/86.jpg)
86
Postmenopausal women at high risk for breast cancer should now have a choice
![Page 87: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/87.jpg)
87
• Well established, FDA approved agent for prevention and treatment of osteoporosis
• Reduced risk of invasive breast cancer observed in MORE has been confirmed in RUTH and STAR
• Clinically important benefit for these women
Raloxifene and Postmenopausal Women with Osteoporosis
![Page 88: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/88.jpg)
88
Invasive Breast Cancer and Vertebral Fracture MORE and P-1
Clinical Vertebral Fracture
(No. per 1000/yr)
Inva
siv
e B
reas
t C
an
cer
(No
. pe
r 1
000
/yr)
MORE
Placebo
P-1 (age≥50)
Placebo
0
2
4
6
8
10
12
0 2 4 6 8 10 12
![Page 89: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/89.jpg)
89
Invasive Breast Cancer and Vertebral Fracture MORE and P-1
Clinical Vertebral Fracture
(No. per 1000/yr)
Inva
siv
e B
reas
t C
an
cer
(No
. pe
r 1
000
/yr)
0
2
4
6
8
10
12
0 2 4 6 8 10 12
P-1 (age≥50)
Placebo
Tamoxifen
3.6 fewer
MORE
Placebo
Raloxifene
3.1 fewer
![Page 90: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/90.jpg)
90
Clinical Vertebral Fracture
(No. per 1000/yr)
Inva
siv
e B
reas
t C
an
cer
(No
. pe
r 1
000
/yr)
MORE
Placebo
P-1 (age≥50)
Placebo
0
2
4
6
8
10
12
0 2 4 6 8 10 12
Raloxifene
3.1 fewer
3.6 fewer
Tamoxifen
0.5 fewer 5.2 fewer
Invasive Breast Cancer and Vertebral Fracture MORE and P-1
![Page 91: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/91.jpg)
91
Postmenopausal women considering raloxifene for treatment of osteoporosis should be informed about the potential
additional benefit on their risk of invasive breast cancer
![Page 92: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/92.jpg)
92
Conclusion
• Since 1998 an estimated 22 million postmenopausal women worldwide have received raloxifene to prevent or treat osteoporosis.
• Clinical trials involving more than 37,000 postmenopausal women now provide information on the benefits and risks of the use of raloxifene to reduce the risk of invasive breast cancer.
• The benefit-risk is favorable in postmenopausal women at high risk for breast cancer and in postmenopausal women taking raloxifene for osteoporosis.
![Page 93: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/93.jpg)
![Page 94: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/94.jpg)
94
Placebo RLX N=5057 N=5044 Hazard Ratio Stroke n (%) n (%) (95% CI) p-Valuea
1 year 35 (0.7) 40 (0.8) 1.14 (0.73, 1.80) .5596
2 year 73 (1.4) 82 (1.6) 1.12 (0.82, 1.54) .4806
3 year 118 (2.3) 124 (2.5) 1.04 (0.81, 1.34) .7440
4 year 148 (2.9) 167 (3.3) 1.12 (0.90, 1.39) .3253
5 year 187 (3.7) 216 (4.3) 1.14 (0.94, 1.39) .1815
6 year 221 (4.4) 242 (4.8) 1.08 (0.90, 1.30) .3936
7 year 224 (4.4) 249 (4.9) 1.10 (0.92, 1.32) .3034
ap-value obtained from log-rank test
Time to Event Analysis of Stroke by Year All Randomized Patients
RUTH
![Page 95: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/95.jpg)
95
Stroke Across Studies
0
2
4
6
8
10
12
RUTH MORE STAR P-1 (age ≥50)
Placebo
Raloxifene
Inci
denc
e pe
r 10
00 w
oman
-yrs
(N=10,101) (N=7705) (N=19,487) (N=8018)
P=0.19
P=0.30
P=0.82
P=0.04
Tamoxifen
![Page 96: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/96.jpg)
96
Evista Label Update: Precautions and Warnings
Death Due to Stroke
Section 5.3 Death Due to Stroke
In a clinical trial of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with EVISTA. During an average follow-up of 5.6 years, 59 (1.2%) EVISTA -treated women died due to a stroke compared to 39 (0.8%) placebo-treated women (22 versus 15 per 10,000 women-years; hazard ratio 1.49; 95% confidence interval, 1.00-2.24; p=0.0499). There was no statistically significant difference between treatment groups in the incidence of stroke (249 in EVISTA [4.9%] versus 224 placebo [4.4%]). EVISTA had no significant effect on all-cause mortality. The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking [see Clinical Studies (14.4)].
![Page 97: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/97.jpg)
97
Proportion of Tamoxifen Efficacy Retained by Raloxifene (Invasive Breast Cancer)
Rothmann Analysis
% Tamoxifen Effect Retained (95% CI)
0 20 40 60 80 100 120 140 160 180
Source for Historical Effect Data
P-1 (>50)
P-1
Cuzick meta-analysis (>50)
Cuzick meta-analysis
![Page 98: 1 Raloxifene for the Reduction in the Risk of Invasive Breast Cancer July 24, 2007 Eli Lilly and Company Oncologic Drugs Advisory Committee Presentation.](https://reader036.fdocuments.net/reader036/viewer/2022062408/56649f135503460f94c26e53/html5/thumbnails/98.jpg)
98
Trial Study Population and Duration
Primary Endpoint Enrollment Criteria Use of ET (%)During the Study
Royal Marsden
N=24711986-1996European Trial
Occurrence of breast cancer
High risk and family history of breast cancer
Yes, 26%
Italian N=54081992-1997European Trial
Occurrence of breast cancer and deaths from breast cancer
Normal risk and hysterectomy
Yes, not reported
P-1 N=13,3881992-1997North American Trial
Occurrence of invasive breast cancer
5 year risk of invasive breast cancer ≥1.66% or had a history of LCIS or atypical hyperplasia
No
IBIS-I N=71391992-2001European Trial
Occurrence of breast cancer including DCIS
Had risk factors for breast cancer with at least 2-fold relative risk
Yes, 40%
Four Tamoxifen Breast Cancer Prevention TrialsStudy Design